Jurjees Hasan

1.7k total citations
53 papers, 919 citations indexed

About

Jurjees Hasan is a scholar working on Oncology, Reproductive Medicine and Cancer Research. According to data from OpenAlex, Jurjees Hasan has authored 53 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 23 papers in Reproductive Medicine and 10 papers in Cancer Research. Recurrent topics in Jurjees Hasan's work include Ovarian cancer diagnosis and treatment (23 papers), PARP inhibition in cancer therapy (10 papers) and BRCA gene mutations in cancer (9 papers). Jurjees Hasan is often cited by papers focused on Ovarian cancer diagnosis and treatment (23 papers), PARP inhibition in cancer therapy (10 papers) and BRCA gene mutations in cancer (9 papers). Jurjees Hasan collaborates with scholars based in United Kingdom, Greece and United States. Jurjees Hasan's co-authors include Gordon C. Jayson, Richard Byers, Andrew R. Clamp, Steven D. Shnyder, M. Bibby, John A. Double, Saifee Mullamitha, Mark Saunders, Juan W. Valle and A. S. McNeilly and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Jurjees Hasan

51 papers receiving 906 citations

Peers

Jurjees Hasan

ONCOL

PRM

Eleni Timotheadou Greece

Aránzazu Manzano Spain

Stefano Tamberi Italy

George Zarkavelis Greece

Jiřı́ Petera Czechia

Suzanne Berlin United States

J.T. Thigpen

Jamie Lesnock United States

Veronika Seebacher Austria

L. Kayitalire France

Eleni Timotheadou Greece

Jurjees Hasan

616 ×1.7

ONCOL

303 ×0.9

95 ×0.5

222 ×1.1

PRM

201 ×1.1

Citations per year, relative to Jurjees Hasan Jurjees Hasan (= 1×) peers Eleni Timotheadou

Countries citing papers authored by Jurjees Hasan

Since Specialization

Citations

This map shows the geographic impact of Jurjees Hasan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jurjees Hasan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jurjees Hasan more than expected).

Fields of papers citing papers by Jurjees Hasan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jurjees Hasan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jurjees Hasan. The network helps show where Jurjees Hasan may publish in the future.

Co-authorship network of co-authors of Jurjees Hasan

This figure shows the co-authorship network connecting the top 25 collaborators of Jurjees Hasan. A scholar is included among the top collaborators of Jurjees Hasan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jurjees Hasan. Jurjees Hasan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morgan, Robert D., Xin Wang, Jurjees Hasan, et al.. (2024). Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer. British Journal of Cancer. 131(12). 1919–1927. 5 indexed citations

Kamposioras, Konstantinos, Panagiotis Ntellas, Katerina Dadouli, et al.. (2024). Longitudinal Follow-Up of the Psychological Well-Being of Patients with Colorectal Cancer: Final Analysis of PICO-SM. Current Oncology. 31(12). 7903–7913.

Morgan, Robert D., George J. Burghel, Hélene Schlecht, et al.. (2024). Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene. Genetics in Medicine. 26(10). 101230–101230. 5 indexed citations

Angelakas, Angelos, Konstantinos Kamposioras, Jorge Barriuso, et al.. (2024). Is early-onset colorectal cancer an evolving pandemic? Real-world data from a tertiary cancer center. The Oncologist. 29(12). e1680–e1691. 1 indexed citations

Lim, Kok Haw Jonathan, Panagiotis Ntellas, Michael Braun, et al.. (2023). The Mental Health Burden of Patients with Colorectal Cancer Receiving Care during the COVID-19 Pandemic: Results of the PICO-SM Study. Cancers. 15(4). 1226–1226. 3 indexed citations

Morgan, Robert D., George J. Burghel, Michael Bulman, et al.. (2023). Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?. Cancers. 15(3). 730–730. 2 indexed citations

Morgan, Robert D., George J. Burghel, Hélene Schlecht, et al.. (2023). Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer. Cancers. 16(1). 177–177. 2 indexed citations

Kamposioras, Konstantinos, Kok Haw Jonathan Lim, Joseph Williams, et al.. (2021). Modification to Systemic Anticancer Therapy at the Start of the COVID-19 Pandemic and its Overall Impact on Survival Outcomes in Patients with Colorectal Cancer. Clinical Colorectal Cancer. 21(2). e117–e125. 6 indexed citations

Kamposioras, Konstantinos, Mark Saunders, Kok Haw Jonathan Lim, et al.. (2020). The Impact of Changes in Service Delivery in Patients With Colorectal Cancer During the Initial Phase of the COVID-19 Pandemic. Clinical Colorectal Cancer. 20(2). e120–e128. 17 indexed citations

10.

Morgan, Robert D., Susana Banerjee, Marcia Hall, et al.. (2020). Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecologic Oncology. 156(3). 545–551. 18 indexed citations

11.

Cairns, Rob A., George J. Burghel, Saifee Mullamitha, et al.. (2020). P-332 Real-world data study of BRAF mutant metastatic colorectal cancer patients across the Greater Manchester region prior to BEACON trial results. Annals of Oncology. 31. S197–S197. 1 indexed citations

12.

Hall, Marcia, Gianfilippo Bertelli, Clare Green, et al.. (2019). Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. International Journal of Gynecological Cancer. 30(2). 213–220. 19 indexed citations

13.

Morgan, Robert D., Richard Welch, Claire Mitchell, et al.. (2019). Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer. ESMO Open. 4(2). e000463–e000463. 7 indexed citations

14.

Saunders, Christobel, Michael Braun, G. Wilson, et al.. (2017). Rapid Analysis of Outcomes Using the Systemic Anti-Cancer Therapy (SACT) Dataset. Clinical Oncology. 29(7). e134–e136. 2 indexed citations

15.

Khoja, Leila, Laura Horsley, Ann Heesters, et al.. (2016). Does clinical trial participation improve outcomes in patients with ovarian cancer?. ESMO Open. 1(4). e000057–e000057. 6 indexed citations

16.

Metcalf, Robert L., et al.. (2014). Thrombosis in ovarian cancer: a case control study. British Journal of Cancer. 110(5). 1118–1124. 38 indexed citations

17.

Khoja, Leila, R. Swindell, Mark Saunders, et al.. (2013). Evaluation of Hypertension and Proteinuria as Markers of Efficacy in Antiangiogenic Therapy for Metastatic Colorectal Cancer. Journal of Clinical Gastroenterology. 48(5). 430–434. 23 indexed citations

18.

O’Connor, James P.B., Alan Jackson, Geoff J.M. Parker, et al.. (2010). Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Annals of Oncology. 21(10). 1982–1989. 25 indexed citations

19.

Hasan, Jurjees, et al.. (2004). Quantitative Angiogenesis Assays in vivo – A Review. Angiogenesis. 7(1). 1–16. 76 indexed citations

20.

Hasan, Jurjees, Richard Byers, & Gordon C. Jayson. (2002). Intra-tumoural microvessel density in human solid tumours. British Journal of Cancer. 86(10). 1566–1577. 242 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact